Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (P30 CA023100)
Received: 13 July 2022
Accepted: 11 August 2022
First Online: 28 August 2022
: This study was performed in accordance with the guidelines of the UCSD Internal Review Board (PREDICT [Profile Related Evidence Determining Individualized Cancer Therapy] protocol; NCT02478931, and/or I-PREDICT [Investigation of Profile Related Evidence Determining Individualized Cancer Therapy] protocol; NCT02534675). Both of these protocols are investigational studies for which the patients gave consent.
: Consent for publication was obtained from the patient.
: HEP, JJA have no conflicts of interest. PD is a fulltime employee at Aver Cancer Institute and a paid consultant at Viecure. SK serves as a consultant for Foundation Medicine, NeoGenomics and CureMatch. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. JKS receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, QED Therapeutics, and has stock in Personalis. VS reports a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study. Vivek Subbiah also reports research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, and Medimmune; travel funds from Pharmamar, Incyte, ASCO, and ESMO; other support from Medscape; all outside the submitted work. RK has receivedresearch funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Grifols, and Guardant, as well as consultant fees from Loxo, X Biotech, NeoMed, Biologic Dynamics, Roche, Iylon, Daiichi, and Actuate Therapeutics, speaker fees from Roche, and has an ownership interest in IDbyDNA and Curematch Inc and CureMetrix and is a Board member of CureMatch and CureMetrix Inc.